drugset / Trial / NCT07619001
A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Participations
RandomizedParallel-groupQuadruple-blindOther
Summary
This study is to evaluate the pharmacokinetic (PK) similarity of AK104 (an anti-PD-1/CTLA-4 bispecific antibody) from the proposed new manufacturing site and the approved original site in healthy male participants.
Timeline
- Start
- 2026-06-01
- Primary completion
- 2026-09-30
- Completion
- 2026-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | 0.2 mg/kg | Intravenous |
Indications
No indication recorded.